About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Pleco Therapeutics raises €17.3M to develop AML product

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

Astellas ‘encouraged’ by menopause symptom treatment results in China

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Abivax pulls in €49.2M but needs more to complete ulcerative colitis program

Neukio Biotherapeutics completes financing round for development of cell therapy products

ADVERTISEMENT

Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain

Manus Bio receives additional funding to fight malaria with biotech

New discovery could lead to drug development for brain cancer

Proxidrugs: a new tool to fight pathogens?

Provention Bio looks to advance diabetes drug through $125M loan

Labiotech adds conference and event listings

ADVERTISEMENT